Acarix AB (publ) (ACARIX) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Acarix Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.659 Good morning, everybody. Thank you for joining the Carex Q2 2025 earnings update. 00:00:04.659 -- 00:00:08.266 Appreciate everybody joining. And as usual, we will give a little bit of an update on 00:00:08.266 -- 00:00:13.034 who we are and what we do for any new investors that are joining us for the first time. 00:00:13.034 -- 00:00:17.923 Carex has the CADScore technology, which is an early cardiac diagnostic tool that is 00:00:17.923 -- 00:00:22.171 implemented at point of care that can help in really rapid assessment of coronary artery 00:00:22.171 -- 00:00:26.789 disease. We have an incredible negative predictive value that's proven by clinical trials, 00:00:26.789 -- 00:00:30.474 and we are the only company in the world in this space that has gone head-to-head with 00:00:30.474 -- 00:00:34.019 the standard of care, which is CTA in our clinical trials. 00:00:34.019 -- 00:00:39.186 In those clinical trials, per FDA approval, we have a 96.2% negative 00:00:39.186 -- 00:00:43.592 predictive value, and in Europe, with the CE mark, we have a 97.2 predictive value. 00:00:43.592 -- 00:00:48.759 Well on course, and if not better, than more invasive and longer timeline testing for 00:00:48.759 -- 00:00:51.297 risk stratification in coronary artery disease. 00:00:51.297 -- 00:00:56.342 We've been in business for over 15 years, have R&D going for the entire period. 00:00:56.342 -- 00:01:00.487 We have 45 patents to date, and we have over 6,000 patients in clinical trials and over 00:01:00.487 -- 00:01:06.093 47,000 uses worldwide. Fairly mature company for a relatively startup organization 00:01:06.093 -- 00:01:09.316 as we function today. As mentioned, we're a class two device. 00:01:09.316 -- 00:01:14.202 We have FDA approval as well a...